PROQR THRAPEUTICS N V's ticker is PRQR and the CUSIP is N71542109. A total of 43 filers reported holding PROQR THRAPEUTICS N V in Q3 2020. The put-call ratio across all filers is 6.00 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $127,000 | -96.7% | 15,896 | -96.5% | 0.03% | -93.7% |
| Q3 2021 | $3,793,000 | +24.2% | 453,182 | 0.0% | 0.41% | +50.0% |
| Q2 2021 | $3,054,000 | +1.9% | 453,182 | 0.0% | 0.27% | +19.1% |
| Q1 2021 | $2,996,000 | +57.4% | 453,182 | 0.0% | 0.23% | +56.5% |
| Q4 2020 | $1,903,000 | -30.9% | 453,182 | 0.0% | 0.15% | -52.6% |
| Q2 2020 | $2,755,000 | +12.1% | 453,182 | +1.2% | 0.31% | -34.0% |
| Q1 2020 | $2,458,000 | -44.7% | 447,657 | -0.3% | 0.47% | -70.1% |
| Q4 2019 | $4,448,000 | +65.8% | 448,880 | -3.6% | 1.57% | -6.5% |
| Q3 2019 | $2,682,000 | -36.7% | 465,580 | 0.0% | 1.68% | +10.9% |
| Q2 2019 | $4,237,000 | +379.8% | 465,580 | +631.1% | 1.52% | +791.8% |
| Q1 2019 | $883,000 | – | 63,680 | – | 0.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 748,861 | $6,815,000 | 2.37% |
| Opus Point Partners Management, LLC | 138,461 | $1,260,000 | 1.86% |
| RTW INVESTMENTS, LP | 3,722,950 | $33,879,000 | 1.81% |
| Kerrisdale Advisers, LLC | 465,580 | $4,237,000 | 1.52% |
| DAFNA Capital Management LLC | 261,521 | $2,380,000 | 0.90% |
| SPHERA FUNDS MANAGEMENT LTD. | 470,000 | $4,277,000 | 0.58% |
| Artal Group S.A. | 1,300,000 | $11,830,000 | 0.48% |
| Orbimed Advisors | 1,382,502 | $12,581,000 | 0.20% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 56,000 | $511,000 | 0.19% |
| ALTRINSIC GLOBAL ADVISORS LLC | 201,360 | $1,832,000 | 0.08% |